Search Tufts Medicine

This qualitative and feasibility study will involve the development, distribution, and evaluation of “period kits” for 15-25 pre-menarchal adolescents with intellectual and developmental disabilities (IDD) (e.g., autism, Asperger’s syndrome, and Down syndrome) in relieving stress and augmenting preparedness concerning menstruation and other imminent pubertal changes. 

Men with severe symptoms of bladder outlet obstruction often have associated bladder fibrosis leading to diminished bladder contractility. Planning to perform a pilot study using 10 urine samples from controls without urinary symptoms and from 10 men with severe urinary symptoms as noted on the International Prostate Symptom Score (IPSS) questionnaire. Assays will determine levels of collagen within the urine samples from both groups.

This study assess if it is possible to provide produce as a prescription in prenatal clinical care for pregnant women and to understand the impact that may have on their health and the health of their newborns after delivery.

Eligible subjects are selected from a registry maintained by the Clinical Site: Cornea Research Foundation of America (CRFA) In Indianapolis. Registry patients are individuals who underwent corneal surgery at the Price Vision Group and whose intraocular pressure was tracked over at least a 6-month period following their surgery and follow-up treatment with steroids. The patients" clinical data resides in the registry. Thus, ONLY CRFA registry patients are eligible for recruitment to the study.

Age-related macular degeneration (AMD) is a disease that affects the retina, an integral part of the eye responsible for sensing light and relaying images to the brain. In the United States, AMD is the leading cause of irreversible vision loss as people age. Previous studies have shown that the nutrients lutein and zeaxanthin can help protect against AMD in middle aged and older adults. These nutrients form a pigment in the retina (macular pigment) that helps protect the retina from light damage.

This is a single site, prospective, cross-sectional, controlled clinical study on a total of 66 subjects. The subjects are divided into two groups: HS non-responders (33 subjects) and HS responders (33 subjects). After completion of questionnaires, the subjects will undergo DED testing and functional nerve testing. Subjects who qualify will be dispensed 4 weeks of preservative free artificial tears and instructed to instill one drop into each eye twice daily.

Low IGF-1 levels in extremely preterm infants (gestational age [GA] of 23 weeks +0 days to 27 weeks +6 days) are a risk factor for CLD and other complications of extreme prematurity. An increase of serum IGF-1 levels provided by SHP607 administration may reduce the incidence of CLD and other complications of extreme prematurity.

The aim of this study is to investigate the use of benralizumab in patients with eosinophilic CRSwNP, and comorbid asthma, whose severity is consistent with a need for surgery despite ongoing treatment with intranasal corticosteroids and a history of treatment with systemic corticosteroids or prior surgery for CRSwNP. The effect of benralizumab 30 mg on nasal polyps will be assessed on top of standard of care therapy with INCS over a 56-week treatment period.

The purpose of this study is to find out about the safety and efficacy of VK2809 for the treatment of non-alcoholic steatohepatitis (NASH).

The purpose of this study is to evaluate the safety and effectiveness of the Vanquish Water Vapor Ablation Device (“Vanquish”) in subjects with Gleason Grade Group 2 (GGG2) localized intermediate-risk prostate cancer